Recommend Galliprant as first-line treatment
Go to GalliprantVet.com for more information
*Approved for use in dogs older than 9 months of age and greater than 8 pounds.
‡Monitoring is recommended if used long-term.
FIRST-IN-CLASS non-COX inhibiting NSAID
1
MODE OF ACTION TARGETS canine OA pain and inflammation while reducing
the impact on GI, kidney, and liver homeostasis
1,2‡
FOR ALL STAGES of OA from the earliest clinical signs
*
Simple, once-daily chewable tablet
INDICATION
Galliprant is an NSAID that controls pain and inflammation associated with osteoarthritis in dogs.
IMPORTANT SAFETY INFORMATION
Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets
in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is
used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting
NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The
safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or
lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. For full
prescribing information see Galliprant package insert.
1. Kirkby Shaw, K, et al. Vet Med Sci. 2016;2:3-9.
2. Rausch-Derra L, et al. Am J Vet Intern Med. 2015;76(10):853-859.
Galliprant, Elanco and the diagonal bar logo are trademarks of Elanco or its a™liates. © 2021 Elanco or its a™liates. PM-US-20-1498
Are your patients getting the
canine osteoarthritis (OA)
pain and inflammation
relief they need?
